Biotech and drug stocks, collectively, are down an average of 16% over the past three months. The closely watched XBI index ...

This acquisition marks a significant step in Jubilant Biosys' global strategy, providing a foothold in Europe's expanding ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.

Figure 1: Schumpeterian trilogy applied to the pharma ecosystem. &nbsp ... usually resulting from curiosity-led research. In biotech, this might be identifying a new pathway involved in disease ...

“If small biotech companies like ours are forced to scale back or shut down, it will not just be a loss for scientific ...

Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven ...

“Through this partnership, we will have a global impact in solving complex problems in the pharmaceutical and biopharmaceutical manufacturing ecosystem.” The consortium will elevate and enhance ...